Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?

Primary Care Diabetes

Volumn 4, Issue 3, 2010, Pages 129-137

  Ahmed, Mohamed H ^a   Abu, Emmanuel O ^a   Byrne, Christopher D ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cardiovascular diseases (CVDs); Metabolic syndrome; Non alcoholic Fatty Liver Disease (NAFLD)

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; GLITAZONE DERIVATIVE; GLUCOSE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTERIAL WALL THICKNESS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RESPONSE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ECHOGRAPHY; EXERCISE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID PEROXIDATION; LIPID STORAGE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER PROTECTION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GENERAL PRACTICE; HUMANS; OBESITY; ORGANIZATIONAL OBJECTIVES; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROGNOSIS; REGIONAL HEALTH PLANNING; RISK FACTORS;

EID: 77957332990     PISSN: 17519918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcd.2010.02.004     Document Type: Review

References (53)

1. M.H.B.C. Ahmed Non alcoholic steatatohepatitis and metabolic syndrome C. Byrne, S. Wild, Metabolic Syndrome 2005 John Wiley & Sons Chichester, UK 279 305
2. M.H. Ahmed Biochemical markers: the road map for the diagnosis of nonalcoholic fatty liver disease Am. J. Clin. Pathol. 127 1 2007 20 22
3. M.H.B.C. Ahmed Metabolic syndrome, diabetes and CHD risk C.J. Packard, The Year in Lipid Disorders 2007 Clinical Publishing Oxford, UK 3 26
4. I. Grattagliano, G. D'Ambrozio, V.O. Palmieri, A. Moschetta, G. Palasciano, and P. Portincasa Improving nonalcoholic fatty liver disease management by general practitioners: a critical evaluation and impact of an educational training program J. Gastrointestin. Liver Dis. 17 4 2008 389 394
5. J.B. Kallman, A. Arsalla, V. Park, S. Dhungel, P. Bhatia, and D. Haddad Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians Aliment Pharmacol. Ther. 29 9 2009 1019 1024
6. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, and J.C. Cohen Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 6 2004 1387 1395
7. L.S. Szczepaniak, P. Nurenberg, D. Leonard, J.D. Browning, J.S. Reingold, and S. Grundy Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am. J. Physiol. Endocrinol. Metab. 288 2 2005 E462 E468
8. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 42 1 2005 44 52
9. S. Bellentani, G. Saccoccio, F. Masutti, L.S. Croce, G. Brandi, and F. Sasso Prevalence of and risk factors for hepatic steatosis in Northern Italy Ann. Intern. Med. 132 2 2000 112 117
10. J.B. Dixon, P.S. Bhathal, and P.E. O'Brien Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese Gastroenterology 121 1 2001 91 100
11. S. Jimba, T. Nakagami, M. Takahashi, T. Wakamatsu, Y. Hirota, and Y. Iwamoto Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults Diabet. Med. 22 9 2005 1141 1145
12. H.J. Kim, H.J. Kim, K.E. Lee, D.J. Kim, S.K. Kim, and C.W. Ahn Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults Arch. Intern. Med. 164 19 2004 2169 2175
13. D.N. Amarapurkar, E. Hashimoto, L.A. Lesmana, J.D. Sollano, P.J. Chen, and K.L. Goh How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J. Gastroenterol. Hepatol. 22 6 2007 788 793
14. S. Kojima, N. Watanabe, M. Numata, T. Ogawa, and S. Matsuzaki Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background J. Gastroenterol. 38 10 2003 954 961
15. J.G. Fan, J. Zhu, X.J. Li, L. Chen, Y.S. Lu, and L. Li Fatty liver and the metabolic syndrome among Shanghai adults J. Gastroenterol. Hepatol. 20 12 2005 1825 1832
16. L. Shen, J.G. Fan, Y. Shao, M.D. Zeng, J.R. Wang, and G.H. Luo Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey World J. Gastroenterol. 9 5 2003 1106 1110
17. J.G. Fan, J. Zhu, X.J. Li, L. Chen, L. Li, and F. Dai Prevalence of and risk factors for fatty liver in a general population of Shanghai, China J. Hepatol. 43 3 2005 508 514
18. A.Y. El Hassan, E.M. Ibrahim, F.A. al-Mulhim, A.A. Nabhan, and M.Y. Chammas Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management Br. J. Radiol. 65 777 1992 774 778
19. D.H. Akbar, and A.H. Kawther Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics Diabetes Care 26 12 2003 3351 3352
20. J.B. Schwimmer, R. Deutsch, T. Kahen, J.E. Lavine, C. Stanley, and C. Behling Prevalence of fatty liver in children and adolescents Pediatrics 118 4 2006 1388 1393
21. G. Radetti, W. Kleon, J. Stuefer, and K. Pittschieler Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging Acta Paediatr. 95 7 2006 833 837
22. S. Dam-Larsen, M. Franzmann, I.B. Andersen, P. Christoffersen, L.B. Jensen, and T.I. Sorensen Long term prognosis of fatty liver: risk of chronic liver disease and death Gut 53 5 2004 750 755
23. L.A. Adams, J.F. Lymp, S.J. St, S.O. Sanderson, K.D. Lindor, and A. Feldstein The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 1 2005 113 121
24. E. Fassio, E. Alvarez, N. Dominguez, G. Landeira, and C. Longo Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies Hepatology 40 4 2004 820 826
25. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, and A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 6 1999 1413 1419
26. P. Angulo, J.C. Keach, K.P. Batts, and K.D. Lindor Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 6 1999 1356 1362
27. J.M. Hui, J.G. Kench, S. Chitturi, A. Sud, G.C. Farrell, and K. Byth Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C Hepatology 38 2 2003 420 427
28. V. Ratziu, L. Bonyhay, M.V. Di, F. Charlotte, L. Cavallaro, and M.H. Sayegh-Tainturier Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis Hepatology 35 6 2002 1485 1493
29. R. Rocha, H.P. Cotrim, F.M. Carvalho, A.C. Siqueira, H. Braga, and L.A. Freitas Body mass index and waist circumference in non-alcoholic fatty liver disease J. Hum. Nutr. Diet. 18 5 2005 365 370
30. G. Pagano, G. Pacini, G. Musso, R. Gambino, F. Mecca, and N. Depetris Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association Hepatology 35 2 2002 367 372
31. S. Chitturi, S. Abeygunasekera, G.C. Farrell, J. Holmes-Walker, J.M. Hui, and C. Fung NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome Hepatology 35 2 2002 373 379
32. A. Gastaldelli, M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi, and A. Mitrakou Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population Hepatology 49 5 2009 1537 1544
33. G. Targher, L. Bertolini, F. Poli, S. Rodella, L. Scala, and R. Tessari Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients Diabetes 54 12 2005 3541 3546
34. R.N. Guzder, W. Gatling, M.A. Mullee, R.L. Mehta, and C.D. Byrne Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study Diabet. Med. 22 5 2005 554 562
35. R.N. Guzder, W. Gatling, M.A. Mullee, and C.D. Byrne Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes Diabetologia 49 1 2006 49 55
36. H.B. Holt, S.H. Wild, P.J. Wood, J. Zhang, A.A. Darekar, and K. Dewbury Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects Diabetologia 49 1 2006 141 148
37. A.J. McCullough The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease Clin. Liver Dis. 8 3 2004 521 533 viii
38. K.G. Tolman, V. Fonseca, M.H. Tan, and A. Dalpiaz Narrative review: hepatobiliary disease in type 2 diabetes mellitus Ann. Intern. Med. 141 12 2004 946 956
39. P. Jousilahti, D. Rastenyte, and J. Tuomilehto Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke Stroke 31 8 2000 1851 1855
40. G. Wannamethee, S. Ebrahim, and A.G. Shaper Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes Am. J. Epidemiol. 142 7 1995 699 708
41. R.K. Schindhelm, J.M. Dekker, G. Nijpels, L.M. Bouter, C.D. Stehouwer, and R.J. Heine Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study Atherosclerosis 191 2 2007 391 396
42. G.N. Ioannou, N.S. Weiss, E.J. Boyko, D. Mozaffarian, and S.P. Lee Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States Hepatology 43 5 2006 1145 1151
43. M. Monami, G. Bardini, C. Lamanna, L. Pala, B. Cresci, and P. Francesconi Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study Metabolism 57 3 2008 387 392
44. G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, and L. Zenari Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 5 2007 1212 1218 (Pubitemid 46684650)
45. G. Targher, L. Bertolini, R. Padovani, F. Poli, L. Scala, and R. Tessari Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease Diabet. Med. 23 4 2006 403 409
46. A.L. Fracanzani, L. Burdick, S. Raselli, P. Pedotti, L. Grigore, and G. Santorelli Carotid artery intima-media thickness in nonalcoholic fatty liver disease Am. J. Med. 121 1 2008 72 78
47. H. Volzke, D.M. Robinson, V. Kleine, R. Deutscher, W. Hoffmann, and J. Ludemann Hepatic steatosis is associated with an increased risk of carotid atherosclerosis World J. Gastroenterol. 11 12 2005 1848 1853
48. G. Targher, L. Bertolini, R. Padovani, F. Poli, L. Scala, and L. Zenari Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients J. Endocrinol. Invest. 29 1 2006 55 60 (Pubitemid 43355836)
49. G. Targher, L. Bertolini, S. Rodella, G. Zoppini, G. Lippi, and C. Day Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients Diabetologia 51 3 2008 444 450
50. M.H. Ahmed, and C.D. Byrne Current treatment of non-alcoholic fatty liver disease Diabetes Obes. Metab. 11 3 2009 188 195
51. M.H. Ahmed, and C.D. Byrne Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD) Drug Discov. Today 12 17-18 2007 740 747
52. C.D. Byrne, R. Olufadi, K.D. Bruce, F.R. Cagampang, and M.H. Ahmed Metabolic disturbances in non-alcoholic fatty liver disease Clin. Sci. (Lond.) 116 7 2009 539 564
53. K.D. Bruce, F.R. Cagampang, M. Argenton, J. Zhang, P.L. Ethirajan, and G.C. Burdge Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression Hepatology 50 6 2009 1796 1808